EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Editorial: Cellular and molecular crosstalk between neural and immune pathologies: unraveling novel common mechanisms and therapeutic targets

Daniel Ortuno-Sahagún, Lenin Pavón, Claudia Azucena Palafox-Sánchez, Dirk M Hermann

Frontiers in Cellular Neuroscience · 02.11.2026 · 20

DOI: 10.3389/fncel.2026.2023909 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Cellular Neuroscience, online erschienen am 02.11.2026. Verfasst von Daniel Ortuno-Sahagún und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Neuroinmunobiología Molecular, Instituto de Neurociencias Traslacionales, Centro Universitario de Ciencias de la Salud, Universidad de…. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nervous and immune systems do not operate independently. They function interdependently, share cells, receptors, and soluble mediators, and they fail together. Glia amplify inflammation, cytokines reshape circuits, autoantibodies breach barriers, and peripheral immune cells remodel axons (Dantzer et al., 2008;Heneka et al., 2015). Multiple sclerosis, Alzheimer's disease, neuropsychiatric systemic lupus erythematosus (NPSLE), major depression, and schizophrenia are therefore not "neurological plus immunological" diseases. They are disorders of a single interface whose cellular and molecular signatures remain incompletely defined (Liddelow et al., 2017;Hickman et al., 2018).This Research Topic was assembled to advance our understanding of this interface from description to mechanism. The aim was not to produce another catalog of immune signals or cytokines in brain disease, but to provide a closer understanding of glia-immune interactions, cytokine-neuron feedback, autoantibody-mediated injury, immunometabolic bridges, and the biomarkers that make those processes measurable. The papers that follow address that goal, spanning astrocytes and senescent glia, mast cells, dendritic cells, kynurenine metabolites, and anti-GAD autoimmunity.Glia are immunocompetent effectors, not bystanders. Luque-Bolivar et al. integrated eleven human astrocyte RNA-seq datasets spanning cytokine, lipid, and pathogen stimuli and recovered a recurrent inflammatory signature of 130 genes, with CXCL10, DDX58, IFIH1, IL-1β, and TLR3 as hubs. The consistency of DDX58 and IFIH1 across dissimilar insults indicates that astrocytes converge on a shared reactive state rather than producing alone stimulus-specific programs. That state is dual: NF-κB and interferon signaling can be protective, but their persistence drives chronic neuroinflammation (Liddelow et al., 2017). Cantero-Fortiz et al. placed the same cells in the aging brain. Senescent astrocytes, microglia, and oligodendrocyte progenitors, together with postmitotic neuronal senescence, sustain a senescence-associated secretory phenotype (SASP) characterized by IL-6, IL-1β, and chemokines that impair proteostasis and synapses. NF-κB, p38 MAPK, mTOR, and cGAS-STING emerged as shared nodes, and the partial overlap of central and peripheral senescence signatures argues for a bidirectional brainbody axis rather than a purely intracranial process (Hickman et al., 2018). Systemic inflammation reaches axons through immunometabolic and serotonergic routes. Maldonado-García et al. presented the kynurenine pathway as a bridge between peripheral cytokine tone and neuroaxonal vulnerability in multiple sclerosis. Cytokines increased indoleamine 2,3-dioxygenase (IDO) gene expression, accelerating and redirecting tryptophan catabolism toward kynurenine, which in turn crosses LAT1. Microglia generate quinolinic acid and 3-hydroxykynurenine, which are highly toxic, whereas astrocytes generate kynurenic acid, which has protective and immunoregulatory functions. Metabolite ratios track plasma neurofilament light chain, cognition, obesityrelated inflammation, and response to exercise. Pérez-Sánchez et al. provided a complementary clinical observation: peripheral serotonin is reduced in women with relapsing-remitting multiple sclerosis who are underweight, have been treated for more than four years, or are receiving IL-1βa. Together, the two papers convert a biochemical pathway into a clinically readable axis: inflammation, tryptophan fate, axonal injury, and psychiatric comorbidity form a single circuit. This pattern is consistent with IDO-driven diversion of tryptophan away from 5-HT synthesis and toward kynurenine, a mechanism long implicated in inflammation-associated mood disturbances (Schwarcz et al., 2012;Miller and Raison, 2016).Autoimmunity inscribes itself in neurons and glia in ways that are reflected in the blood. Reyes-Mata et al. reviewed peripheral markers of neuronal and glial injury in NPSLE. Serum NfL and GFAP levels rise with central nervous system (CNS) involvement, correlate with CSF levels, and associate with focal manifestations and damage indices, to which S100B and sTREM2 add cerebrovascular and microglial dimensions. These are not generic inflammatory analytes; they are downstream products of barrier failure, autoantibody entry, complement activation, and microglial engagement (Prinz and Priller, 2014). Zurayqi et al. illustrate the same principle at the patient bedside in anti-GAD rhombencephalitis with hydrophobia, an atypical presentation of an immune attack on GABAergic neurons. Diagnosis required serologic correlation and exclusion of infection. Immunotherapy produced only partial relief. Autoantibodies that target intracellular enzymes of neurotransmission remain a direct, under-mapped form of neural-immune injury.Peripheral immune cells are sufficient to injure nerves. Hu et al. used Mendelian randomization and single-cell analysis to show that HLA-DR+ dendritic-cell phenotypes increase the risk of diabetic peripheral neuropathy, that several plasma proteins (including MICB and HLA-DRA) are protective, and that pathogenic immune cells suppress these proteins. Single-cell data from the sural nerve confirmed infiltration by conventional dendritic cells and disrupted reparative crosstalk with Schwann cells. Chinnappan et al. found elevated serum IL-11 and MMP-9 in women with myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) and showed that a recombinant EBV protein drives MMP-9 release from human mast cells. Matrix remodeling and mast cell activation thus occupy the same neuroimmune map as dendritic-cell-Schwann cell disruption: tissueresident and circulating leukocytes can alter the extracellular niche of axons without a classical CNS lesion (Kipnis, 2016).The articles in this Research Topic converge on the following general conclusions. First, astrocytes and other glia adopt a recurrent inflammatory program -CXCL10, DDX58, IFIH1, IL-1β, TLR3, and Senescence-Associated Secretory Phenotype (SASP) cytokines -across stimuli and across aging, which can either be protective or pathogenic, based on disease settings (Luque-Bolivar et al.; Cantero-Fortiz et al.). Second, the kynurenine pathway and peripheral serotonin are measurable links among systemic inflammation, disease-modifying therapy, nutritional status, and neuroaxonal and psychiatric outcomes in multiple sclerosis (Maldonado-García et al.; Pérez-Sánchez et al.). Third, serum markers of axonal and astrocytic injury along with autoantibodies against neuronal enzymes can indicate immune-mediated CNS damage when imaging and clinical assessment are incomplete (Reyes-Mata et al.; Zurayqi et al.). Fourth, dendritic cells and mast cells are not merely correlates of neuropathy and post-viral fatigue; they also participate in causal or experimentally demonstrable injury to nerve and matrix (Hu et al.; Chinnappan et al.).From these conclusions, therapeutic implications can be defined as follows: Targets at the shared interface of neural and immune systems -reactive astrocyte hubs; senescent glia and SASP; IDO and kynurenine enzymes; NfL/GFAP-guided monitoring; HLA-DR+ dendritic cells; mast-cell-MMP-9 release; and pathogenic autoantibodies -are more likely to modify both the neural and immune manifestation of neurological diseases than targets confined to one of the two systems. Remaining tasks for future studies include longitudinal, multimodal measurement of targets in the same patients, which may open avenues for reading disease mechanisms and treatments on the same scale. This strategy may open fascinating perspectives that advance patient care in neurological conditions at the neural-immune interface. ). An immunometabolic bridge links peripheral cytokine tone to axonal fate: cytokine-induced IDO diverts tryptophan from serotonin toward kynurenine, which crosses LAT1 and is converted by microglia to excitotoxic quinolinic acid and 3-hydroxykynurenine, or by astrocytes to protective kynurenic acid. Downstream injury -axonal loss, astrogliosis, synaptic failure, and anti-GAD attack on GABAergic neurons -is detectable in blood (NfL, GFAP, S100B, sTREM2, kynurenine ratios, peripheral 5-HT, autoantibodies). These same nodes are candidate therapeutic targets for diseases that occupy this single interface rather than separate neurological and immunological compartments.

Schlagwörter

Stichwörter der Autor:innen

anti-GAD autoimmunitydendritic cell-schwann cell interactionkynurenine pathwaymultiple sclerosisneural-immune crosstalkneurofilament light chain (NFL)reactive astrocytessenescence-associated secretory phenotype

Autor:innen und Institutionen

  • Laboratorio de Neuroinmunobiología Molecular, Instituto de Neurociencias Traslacionales, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
  • Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
  • Laboratorio de Psicoinmunología, Dirección de Investigaciones Biomédicas en Salud Mental, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico.
  • Departamento de Clínicas Médicas, Instituto de Investigación en Medicina Traslacional, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
  • Department of Neurology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Zitieren

APA

Ortuno-Sahagún, D., Pavón, L., Palafox-Sánchez, C. A., & Hermann, D. M. (2026). Editorial: Cellular and molecular crosstalk between neural and immune pathologies: unraveling novel common mechanisms and therapeutic targets. Frontiers in Cellular Neuroscience, 20. https://doi.org/10.3389/fncel.2026.2023909

Vancouver

Ortuno-Sahagún D, Pavón L, Palafox-Sánchez CA, Hermann DM. Editorial: Cellular and molecular crosstalk between neural and immune pathologies: unraveling novel common mechanisms and therapeutic targets. Frontiers in Cellular Neuroscience. 2026;20. doi:10.3389/fncel.2026.2023909

BibTeX
@article{OrtunoSahagn2026,
  author = {Ortuno-Sahagún, Daniel and Pavón, Lenin and Palafox-Sánchez, Claudia Azucena and Hermann, Dirk M},
  title = {Editorial: Cellular and molecular crosstalk between neural and immune pathologies: unraveling novel common mechanisms and therapeutic targets},
  journal = {Frontiers in Cellular Neuroscience},
  year = {2026},
  volume = {20},
  doi = {10.3389/fncel.2026.2023909}
}
Kostenlos starten →